ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...
Q: My doctor just told me that I’m now considered obese. A week ago, I wasn’t — and I haven’t gained any weight. What’s going ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback